A study to test the acceptability, feasibility and potential efficacy of the SAMSON solution for medication adherence in cancer

Not Applicable

Active, not recruiting

• Conditions: Cancer; Cancer - Leukaemia - Chronic leukaemia; Cancer - Malignant melanoma; Cancer - Other cancer types; Cancer - Lung - Mesothelioma; Cancer - Hodgkin's; Cancer - Myeloma; Cancer - Lung - Non small cell; Cancer - Lung - Small cell; Cancer - Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma

• Registration Number: ACTRN12623000472673
• Lead Sponsor: Peter MacCallum Cancer Centre

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-05-09
• Last Update Posted: 8 July 2024

Recruitment & Eligibility

• Status: Active, not recruiting
• Sex: All
• Target Recruitment: 31

Inclusion Criteria

1)A confirmed diagnosis of any-stage haematological, lung or melanoma cancer;
2)Scheduled to commence oral anti-cancer treatment as part of routine care or commencing treatment/currently treated with the medication for less than 12 months;
3)Willing to have oral anti-cancer medication dispensed at Peter Mac;
4)18 years or over;
5)Proficient in English; and
6)Accessibility to the internet and a smartphone and/or computer and telehealth.

Exclusion Criteria

1)Too unwell to participate in the study as determined by the patient’s treatment team.
2)Remaining indication treatment period of oral medications for cancer therapy is less than 12 weeks.
3)Demonstrated cognitive or psychological difficulties that would preclude study participation as defined by the treatment team’s cognitive and/or psychiatric assessment or patient’s disclosed medical history.

Study & Design

• Study Type: Interventional
• Study Design: Not specified